Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > From May/6/2020

<< Previous

Bullboard Posts

Next >>

Comment by Rarbar99on Aug 10, 2021 6:30pm

170 Views

Post# 33682541

RE:From May/6/2020

Dr. Staffer was the global medical director at Abbot Labs, a company that has a $250 BILLION dollar market cap. And you think he's going to put his reputation on the line to swindle for $500K?

do your research before you attempt to spread fud.

<< Previous

Bullboard Posts

Next >>

Rick Rule’s election insights: Gold, USD, and Canadian gas